Avilamycin Pharma Grade API is a fermentation-derived orthosomycin complex produced by selected strains of Streptomyces viridochromogenes. The principal component is avilamycin A, with avilamycin B and related homologues present as minor factors. The product is assigned CAS 69787-79-7 and is supplied in three controlled grades: AVL-PH-STD with D90 ≤ 100 µm, AVL-PH-MIC with D90 ≤ 20 µm, and AVL-PH-STR sterile injectable grade with bacterial endotoxin < 0.5 EU/mg. Avilamycin inhibits protein synthesis by binding to the 50S ribosomal subunit at a site that does not overlap with macrolide or lincosamide binding; this property limits cross-resistance in Gram-positive organisms. The compound is lipophilic and exhibits low aqueous solubility below 1 mg/mL at 25 °C. Release specifications include assay by high-performance liquid chromatography, loss on drying, residue on ignition, residual solvents, and particle size distribution. The API is suitable for tablet, capsule, granule, and injectable dosage form development where regulatory approval permits. The term “pharma grade” refers to compliance with current GMP API release specifications and does not itself establish a marketing authorization for any human medicine. In the United States and the European Union, avilamycin is not authorized as a human pharmaceutical API; development is therefore focused on veterinary dosage forms or jurisdictions with separate approval pathways. Storage is controlled at 2–8 °C in sealed double polyethylene bags under nitrogen.

What Analytical Limits Define Avilamycin Pharma Grade API Release?

The release specification for Avilamycin Pharma Grade API follows current GMP API guidance, ICH Q2(R1) validation requirements, and the applicable general chapters of USP and Ph. Eur. High-performance liquid chromatography with UV detection is used for assay and related substances. The acceptance limits in Table 1 are representative for non-sterile grades; sterile injectable grade adds bacterial endotoxin and sterility testing.

The assay limit for the sum of avilamycin A and avilamycin B is set at ≥ 95.0% because the B factor contributes to total antimicrobial potency. Any single unknown impurity above 2.0% triggers additional identification by liquid chromatography–mass spectrometry. The particle size specifications are not compendial but are manufacturing controls necessary for downstream content uniformity and suspension viscosity. For sterile grade AVL-PH-STR, container closure integrity testing follows USP <1207>; sterility test method suitability is established per USP <71>.

For tablet and capsule manufacture, particle size distribution controls blend uniformity, dissolution, and content uniformity. Standard-grade active pharmaceutical ingredient with D90 ≤ 100 µm is processed through a cone mill fitted with a 600 µm round-hole screen before blending. In low-dose formulations, the milled API is pre-blended with microcrystalline cellulose NF at a ratio of 1:5 in a 600 L bin blender for 15 min at 12 rpm. Subsequent geometric dilution with lactose monohydrate and crospovidone reduces the risk of content uniformity failure. Direct compression is limited by the poor flow of the lipophilic API; roll-compacted dry granulation with microcrystalline cellulose and croscarmellose sodium is preferred when drug loading exceeds 20% w/w. Ribbon density is maintained between 1.15 g/cm³ and 1.25 g/cm³; outside this range, granules show excessive fines or hardness. Tablet compression on a rotary press at 8–20 kN produces tablets with tensile strength above 2 MPa. A recurring failure mode in direct compression is lamination when magnesium stearate is blended for more than 5 min; overlubrication decreases tablet tensile strength from 2.3 MPa to 1.4 MPa and delays dissolution. Content uniformity testing follows USP <905>; milled API with D90 above 120 µm shows unacceptable acceptance value in low-dose batches. Batch-to-batch variance in API particle size, measured by laser diffraction according to ISO 13320, is a primary source of blend uniformity deviation in solid oral dosage forms.

For tablet film coating, aqueous hydroxypropyl methylcellulose-based systems are applied at 10–12% w/w weight gain; pan speed and spray rate are adjusted to maintain bed temperature below 45 °C because the orthosomycin complex shows process-associated assay loss above this threshold in coated tablets. Coating pan exhaust humidity above 65% produces tablet surface defects and increases moisture uptake; the preferred operating range is 35–45% RH at exhaust. The coated tablet specification includes disintegration time not more than 30 min in purified water at 37 °C per USP <701>.

When Lyophilized Injectable Formulations Require Sterile Avilamycin Micronized Grade

For lyophilized injectable formulations, sterile injectable grade AVL-PH-STR is supplied with a bacterial endotoxin limit < 0.5 EU/mg and is tested for sterility according to USP <71>. The powder is micronized to D90 ≤ 20 µm for suspension formulations. Aqueous solubility below 1 mg/mL makes solution parenterals impractical without solubilizing excipients; therefore injectable products are usually suspensions or lyophilized cakes containing tocopheryl polyethylene glycol succinate or poloxamer 188 as wetting agents. The lyophilization cycle requires complete freezing to below −35 °C and primary drying shelf temperature below −10 °C; collapse temperatures for the mannitol–trehalose matrix are measured by freeze-drying microscopy. Terminal sterilization by gamma irradiation is not recommended because the orthosomycin complex can undergo radiolytic degradation; aseptic processing is the defined manufacturing route. The API is stored at 2–8 °C in sealed double polyethylene bags under nitrogen. Exposure to relative humidity above 60% for more than 24 h increases moisture content beyond the specified 1.0% loss-on-drying limit. Published data for the exact stability of this specific injectable configuration are limited; compatibility testing with rubber stopper elastomers should include extractables profiling per USP <1663>. Avoid combination with strong oxidizing agents and alkaline buffers above pH 8.0 unless specific stability data justify the formulation.

Granule and Capsule Filling Process Windows and Excipient Selection

During wet granulation, Avilamycin Pharma Grade API is restricted by the low aqueous solubility and potential thermal sensitivity of the orthosomycin complex. The granulation liquid is typically an aqueous solution containing 5% w/w povidone K30; water is preferred over ethanol to reduce residual solvent burden. In high-shear granulation the optimal water quantity is between 8% and 12% w/w relative to dry mass. At water addition above 15% w/w, granule growth becomes uncontrolled and sieve yield above 1.0 mm increases above 35%, reducing capsule fill weight consistency. Drying is performed in a fluid-bed dryer with inlet air temperature limited to 55 °C; higher temperatures have been associated with assay loss due to thermal degradation. Milled granules are lubricated with 0.5% w/w magnesium stearate for 3 min in a bin blender; longer lubrication times cause hydrophobic film formation and delayed dissolution. Capsule filling is performed on an automatic tamping-pin machine with target fill weight coefficient of variation below 2.0%. The process boundaries are derived from production-scale batch records using equipment classes commonly employed in antibiotic solid dosage form manufacturing. For capsule sizes 0–3, granule bulk density between 0.45 g/mL and 0.60 g/mL is required to stay within the target fill range without excessive compression of the powder bed.

Differences from Macrolide, Lincosamide, and Ionophore APIs Are Detectable by 50S Subunit Binding and Manufacturing Behavior

In comparative evaluation against tylosin tartrate and bacitracin zinc, Avilamycin Pharma Grade API requires different formulation and quality controls. The orthosomycin binding site on the 50S ribosomal subunit does not overlap with the macrolide-binding site; enterococci and staphylococci with erm-mediated macrolide resistance often retain susceptibility to avilamycin. Unlike bacitracin zinc, which acts on cell wall peptidoglycan and is nephrotoxic in parenteral use, avilamycin does not share the same nephrotoxicity profile, although published human safety data are limited. In contrast to ionophore coccidiostats such as monensin and salinomycin, avilamycin does not act by disrupting cation gradients, so it does not share the same species-specific toxicity constraints. In manufacturing, avilamycin has lower aqueous solubility than tylosin tartrate, making wet granulation and injectable suspension design more difficult; particle size reduction is required to achieve acceptable dissolution or suspension wetting. Table 2 summarizes key differences relevant to pharmaceutical processing and quality control.

In direct comparison with ionophore coccidiostats and bacitracin zinc, Avilamycin Pharma Grade API differs in storage and handling requirements. The API must not be stored in unlined polyethylene containers for more than 30 days because the lipophilic orthosomycin complex can adhere to non-polar surfaces and reduce assay recovery during transfer. A dedicated scoops and blending equipment passivation procedure prevents cross-contamination with beta-lactam antibiotics; this is a specific operational boundary for multi-product antibiotic manufacturing facilities. Silicone-free transfer lines are specified because silicone oil can accelerate particle agglomeration in micronized grade AVL-PH-MIC. These physical incompatibilities are derived from production-scale powder handling observations and are not part of the formal release specification. Published data for the exact thermodynamic interaction between silicone oil and micronized avilamycin is limited, but manufacturing records from fluid-bed processing lines support the use of stainless-steel contact surfaces.